Domperidone ( DrugBank: Domperidone )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	6
13	多発性硬化症／視神経脊髄炎	2
17	多系統萎縮症	1
51	全身性強皮症	1
230	肺胞低換気症候群	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03022201 (ClinicalTrials.gov)	May 2013	23/11/2016	Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease	Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial	Parkinson's Disease,Idiopathic	Drug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701	Seoul National University Hospital	NULL	Completed	20 Years	80 Years	All	40	Phase 4	Korea, Republic of
2	NCT02500108 (ClinicalTrials.gov)	May 2013	14/7/2015	Domperidone and Risk of Sudden Cardiac Death	Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death	Parkinson's Disease	Drug: Domperidone	Canadian Network for Observational Drug Effect Studies, CNODES	Drug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR)	Completed	50 Years	N/A	Both	214962	N/A	Canada
3	JPRN-UMIN000007896	2012/05/01	07/05/2012	Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes	Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes - Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes	Parkinson's disease and other parkinsonian syndromes	The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.	Kansai Medical University	NULL	Recruiting	Not applicable	Not applicable	Male and Female	100	Not selected	Japan
4	NCT00305331 (ClinicalTrials.gov)	March 2006	20/3/2006	Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease	Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease	Parkinson's Disease;Peripheral Edema	Drug: Domperidone (drug)	University Health Network, Toronto	NULL	Terminated	30 Years	90 Years	Both	25	Phase 2	Canada
5	NCT00103597 (ClinicalTrials.gov)	January 2005	11/2/2005	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension	Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension	Royal Brisbane and Women's Hospital	NULL	Completed	40 Years	95 Years	Both	50	Phase 1	Australia
6	NCT00006077 (ClinicalTrials.gov)	August 2000	4/8/2000	Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease	Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease	Parkinson's Disease	Drug: NS2330;Drug: Levodopa and Domperidone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	50	Phase 2	United States

先頭へ

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02493049 (ClinicalTrials.gov)	August 2015	2/7/2015	Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)	Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Completed	18 Years	60 Years	All	17	Phase 2	Canada
2	NCT02308137 (ClinicalTrials.gov)	February 2015	2/12/2014	Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis, Secondary Progressive	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Completed	18 Years	60 Years	All	64	Phase 2	Canada

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00103597 (ClinicalTrials.gov)	January 2005	11/2/2005	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy	Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension	Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension	Royal Brisbane and Women's Hospital	NULL	Completed	40 Years	95 Years	Both	50	Phase 1	Australia

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01878526 (ClinicalTrials.gov)	June 2013	7/6/2013	Gastroesophageal Reflux Treatment in Scleroderma	The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis	Gastroesophageal Reflux Disease;Systemic Sclerosis;Scleroderma	Drug: Alginic acid;Drug: placebo (for domperidone);Drug: Domperidone;Drug: placebo (of alginic acid)	Khon Kaen University	NULL	Completed	18 Years	65 Years	All	80	Phase 3	Thailand

230. 肺胞低換気症候群

臨床試験数 : 6 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-005950-33-SE (EUCTR)	07/06/2006	10/04/2006	Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom. - DOMPCCHSSWE1	Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom. - DOMPCCHSSWE1	Congenital central hypoventilation syndrome, CCHS or Ondine's curse.	Trade Name: Motilium Product Name: Motilium INN or Proposed INN: Domperidone	Karolinska Universitetssjukhuset	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Sweden

先頭へ